Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung Adenocarcinomas

被引：0
|
作者：
Pirazzoli, Valentina
Takezawa, Ken
de Stanchina, Elisa
Pao, William
Politi, Katerina
机构：
来源：
CLINICAL CANCER RESEARCH | 2012年 / 18卷 / 10期
关键词：
D O I：
10.1158/1078-0432.MECHRES-A38
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A38
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403
    Goldberg, S.
    Redman, M.
    Lilenbaum, R.
    Politi, K.
    Stinchcombe, T.
    Horn, L.
    Chen, E.
    Mashru, S.
    Gettinger, S.
    Melnick, M. A.
    Miao, J.
    Moon, J.
    Kelly, K.
    Gandaram, D.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S343 - S344
  • [42] Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer
    Tricker, Erin M.
    Xu, Chunxiao
    Uddin, Sharmeen
    Capelletti, Marzia
    Ercan, Dalia
    Ogino, Atsuko
    Pratilas, Christine A.
    Rosen, Neal
    Gray, Nathanael S.
    Wong, Kwok-Kin
    Jaenne, Pasi A.
    [J]. CANCER DISCOVERY, 2015, 5 (09) : 960 - 971
  • [43] ACTIVITY OF AFATINIB/CETUXIMAB IN PATIENTS (PTS) WITH EGFR MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) AND ACQUIRED RESISTANCE (AR) TO EGFR INHIBITORS
    Janjigian, Y. Y.
    Smit, E. F.
    Horn, L.
    Groen, H. J. M.
    Camidge, D. R.
    Gettinger, S.
    Fu, Y.
    Denis, L. J.
    Miller, V.
    Pao, W.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 401 - 401
  • [44] Clinical outcomes for EGFR-mutant adenocarcinomas (AC) that transform to small cell lung cancer (SCLC)
    Marcoux, N.
    Piotrowska, Z.
    Farago, A. F.
    Hata, A. N.
    Mooradian, M. J.
    Drapkin, B. J.
    Muzikansky, A.
    Gettinger, S. N.
    Mino-Kenudson, M.
    Sequist, L.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [45] Optimizing the Sequence of Anti-EGFR-Targeted Therapy in EGFR-Mutant Lung Cancer
    Meador, Catherine B.
    Jin, Hailing
    de Stanchina, Elisa
    Nebhan, Caroline A.
    Pirazzoli, Valentina
    Wang, Lu
    Lu, Pengcheng
    Vuong, Huy
    Hutchinson, Katherine E.
    Jia, Peilin
    Chen, Xi
    Eisenberg, Rosana
    Ladanyi, Marc
    Politi, Katerina
    Zhao, Zhongming
    Lovly, Christine M.
    Cross, Darren A. E.
    Pao, William
    [J]. MOLECULAR CANCER THERAPEUTICS, 2015, 14 (02) : 542 - 552
  • [46] EGFR-mutant lung adenocarcinomas mutation profiles reveal ARID1A might be a novel tyrosine kinase resistance pathway
    Gao, Xuyuan
    Xu, Hang
    Ho, James C. M.
    Chan, Oscar S. H.
    Xu, Feng
    Wang, Junwen
    Lee, Victor H. F.
    Tin, Vicky P. C.
    Xiao, Zhijie
    Wang, Siqi
    Yam, Judy W. P.
    Wong, Maria P.
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [47] The impact of bevacizumab on combination low-dose afatinib and cetuximab therapy in lung cancer cells harboring activated EGFR mutations
    Kudo, Kenichiro
    Ohashi, Kadoaki
    Ichihara, Eiki
    Minami, Daisuke
    Kubo, Hisao
    Sato, Akiko
    Kato, Yuka
    Isozaki, Hideko
    Kayatani, Hiroe
    Tamura, Tomoki
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    [J]. CANCER RESEARCH, 2015, 75
  • [48] Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)
    Bertino, Erin M.
    Gentzler, Ryan D.
    Clifford, Sarah
    Kolesar, Jill
    Muzikansky, Alona
    Haura, Eric B.
    Piotrowska, Zofia
    Camidge, D. Ross
    Stinchcombe, Thomas E.
    Hann, Christine
    Malhotra, Jyoti
    Villaruz, Liza C.
    Paweletz, Cloud P.
    Lau, Christie L.
    Sholl, Lynette
    Takebe, Naoko
    Moscow, Jeffrey A.
    Shapiro, Geoffrey, I
    Janne, Pasi A.
    Oxnard, Geoffrey R.
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (06) : 1604 - 1611
  • [49] Repeated treatment with gefitinib and alectinib in a patient with multiple EGFR-mutant and ALK-mutant lung adenocarcinomas: A case report
    Yorozuya, Takafumi
    Nagano, Yutaro
    Chiba, Hirofumi
    Imai, Yui
    Yasuda, Kento
    Sudo, Yuta
    Taya, Tetsuya
    Shioya, Makoto
    [J]. RESPIRATORY MEDICINE CASE REPORTS, 2021, 32
  • [50] PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
    Sos, Martin L.
    Koker, Miriam
    Weir, Barbara A.
    Heynck, Stefanie
    Rabinovsky, Rosalia
    Zander, Thomas
    Seeger, Jens M.
    Weiss, Jonathan
    Fischer, Florian
    Frommolt, Peter
    Michel, Kathrin
    Peifer, Martin
    Mermel, Craig
    Girard, Luc
    Peyton, Michael
    Gazdar, Adi F.
    Minna, John D.
    Garraway, Levi A.
    Kashkar, Hamid
    Pao, William
    Meyerson, Matthew
    Thomas, Roman K.
    [J]. CANCER RESEARCH, 2009, 69 (08) : 3256 - 3261
12345